5 Key Takeaways

• 1

  EULAR rheumatoid arthritis recommendations favor initial methotrexate, ideally with short-term glucocorticoids, and adding a biologic DMARD if response is insufficient after 3 to 6 months.

• 2

  ACR guidance for systemic lupus erythematosus highlights hydroxychloroquine, limiting glucocorticoid duration, and early immunosuppressive therapy to achieve and maintain remission or low disease acti

• 3

  ACR gout guidance recommends allopurinol as first-line urate-lowering therapy when indicated, dose titration to a serum urate target below 6 mg/dL, and anti-inflammatory prophylaxis for at least 3 to

• 4

  In ORAL Surveillance, tofacitinib did not meet noninferiority criteria versus tumor necrosis factor inhibitors for major cardiovascular events or cancers excluding nonmelanoma skin cancer.

• 5

  ACR identifies 5 preferred rheumatoid arthritis disease activity measures, while FRAX estimates 10-year hip and major osteoporotic fracture probabilities using clinical risk factors and femoral neck b